Neurocrine Biosciences Inc. (NASDAQ: NBIX) named one of the 11 best debt-free stocks to invest in. Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on NBIX with a price target of $165 after a recent investor meeting covering commercial performance and future catalysts.

Management at Neurocrine Biosciences highlighted continued growth in Ingrezza sales, with expectations for Q2 and a strong second half of 2025. They also addressed concerns about potential pricing pressure on TEVA’s Austedo under the Inflation Reduction Act, working toward equal access with TEVA.

The team at NBIX emphasized the significant population of untreated patients, highlighting long-term growth potential for VMAT2 inhibitors. The company focuses on developing treatments for underserved neurological, neuroendocrine, and neuropsychiatric disorders.

While NBIX shows investment potential, some AI stocks offer greater upside with less downside risk. For those interested in undervalued AI stocks poised to benefit from Trump-era tariffs and the onshoring trend, consider checking out the best short-term AI stock.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List